External Affairs

Mar 31, 2022

March 31st, 2022 SUBMITTED ELECTRONICALLY Jacqueline Ward, White House Office of Science and Technology Policy (OSTP) RE: Request for Information on Strengthening Community Health Through Technology On behalf of the..

Jan 17, 2022

November 22nd, 2021 RE: Semiconductor chip shortage impact on Medical Devices The Honorable Gina Raimondo Department of Commerce Washington, D.C. 20500 The Honorable Brian Deese National Economic Council Washington, D.C...

Sep 28, 2021

Washington, DC—California Life Sciences (CLS) is calling on the California Congressional Delegation to support the Orphan Drug Tax Credit (ODTC). CLS has expressed strong concern with Section 138141 of the..

Aug 27, 2021

The restoration of California’s Research and Development (R&D) tax credit and Net Operating Loss (NOL) deduction has been one of California Life Sciences’ (CLS) top priorities for 2021.

Jun 30, 2021

Watch the recap of Conversation with Thought Leaders: Health Equity, which explored the importance of increasing health access to underserved communities and how the life sciences community can help tackle..

Jun 9, 2021

For the 2021-2022 Legislative Session, Senator Susan Eggman (D-Stockton) introduced SB 605, the Medical Device Right to Repair Act, which would allow health care facilities to contract out repairs for..

Jun 3, 2021

On Thursday, June 3, Cal-OSHA met to discuss workplace rules and COVID-19. After meeting for almost 10 hours, the board ultimately voted to allow workers in a room to take..

Mar 26, 2021

The California Life Sciences Association (CLSA) sponsored and introduced Assembly Bill (AB) 593, with Assemblymember Cottie Petrie-Norris (AD 74) which reinstates the Research and Development (R&D) Tax Credit and Net Operating Loss (NOL) deductions for life sciences companies in California for tax years 2021 and 2022.

Mar 24, 2021

Biocom California and the California Life Sciences Association (CLSA) today released data analyzing the potential impact of international reference pricing (foreign price controls) on California’s biopharmaceutical innovation ecosystem, including investment into small company capital formation and the new drug development pipeline.

Jan 28, 2021

Earlier this month, the Centers for Medicare and Medicaid Services (CMS) released the final “Medicare Coverage of Innovative Technology (MCIT) and Definition of ‘Reasonable and Necessary” rule (42 CFR Part 405).  The rule, if implemented as planned in March of this year, creates a pathway for automatic CMS coverage – for 4 years – of medical devices that receive Food and Drug Administration (FDA) breakthrough technologies program designation and subsequent market authorization through their Expedited Review Approval Process.

Jan 27, 2021

On Tuesday, January 26, Governor Newsom revised the vaccine rollout plan to help streamline allocation and distribution. Vaccine distribution will now be led by the Government Operations Agency along with CA Health and Human Services and CA Department of Public Health.

Jan 27, 2021

On Tuesday, January 26th CLSA and BIO hosted a briefing titled, “The Transformative Potential of Gene Therapies” in partnership with the California Select Committee on Biotechnology and the California Rare Disease Caucus. This briefing was moderated by Assemblymember Kevin Mullin and was attended by legislators, legislative staff and members of the rare disease community who are interested in learning more about gene therapies.